shivaani kummar ohsu email shivaani kummar ohsu email

Lisa M. Coussens, M.D. Shivaani Kummar. You may also qualify for Phase 1 Program trials. 12 Reviews). Ashok Muralidaran, M.D., discusses how his passions inspire his work as a pediatric cardiac surgeon. 2001-2022 Oregon Health & Science University. Abstracts & Presentations. Read more to learn about Shivaani Kummar, MBBS's background, education, and other specialties. Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. bard college music faculty. Each study answers scientific questions and tries to find better ways to prevent, diagnose or treat diseases like cancer. Recent external collaboration on country/territory level. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Shivaani Kummar. Only fill in if you are not human. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. Cited by. Visit thebilling andinsurancesection of our sitefor more information. Want to join the faculty at the Knight Cancer Institute? Notice of Privacy Practices Post author By ; aleko lm137 manual Post date July 1, 2022; police clearance certificate in saudi arabia . Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. (h.c.), Ph.D., FAACR. When were developing new treatments for cancer, we are often trying to identify what makes the cancer different from normal cells or why currently used drugs are not working as well as we would like them to. The OHSU Knight Cancer Institute has expanded its cancer research and care facilities to include a unit dedicated to serving patients participating in early-phase clinical trials. This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Cancer Early Detection Advanced Research Center, Adolescent and Young Adult Oncology Program, Social and Emotional Side Effects of Cancer, International Alliance for Early Cancer Detection (ACED), Lisa M. Coussens, M.D. 2001-2022 Oregon Health & Science University. OHSU is an equal opportunity affirmative action institution. Read More Contact Shivaani Kummar's Phone Number and Email Last Update 11/29/2022 2:55 AM Email s***@ohsu.edu Engage via Email Contact Number (***) ***-**** Engage via Phone Mobile Number (***) ***-**** Engage via Mobile HQ Phone What is the importance of philanthropy to your work? Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS. Shivaani Kummar, MBBS is an Oncologist. Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. Dr. Dive into the research topics where Shivaani Kummar is active. (OHSU/Kristyna Wentz-Graff). Dive into details by clicking on the dots or, Knight Cancer Translational Oncology Program, Calculated based on number of publications stored in Pure and citations from Scopus, PQ3: Age-related immune deviation and cancer outcome, [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors, Understanding the origins of rapid recurrence of pancreatic cancer after resection. Administrative Coordinator, Ingrid Studebaker Caring for them drives me to work harder to develop more effective treatments that are better tolerated. You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number - 503-314-7168). . In 2020, 470 Oregon residents from 28 counties consented to participate in clinical trial activities with the Knight Cancer Institute. Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . Year; Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University. boundtree continuing education; can you be charged under ucmj after discharge Having someone who understands the challenges is helpful.. . Over the past six months, a multidisciplinary team has been coordinating patient experience, drug delivery, staffing schedules and equipment needed to support the range of clinical trials offered in the unit that span 14 different cancer disease groups. Within our Center for Experimental Therapeutics, Knight Cancer Institute, we have multiple ongoing projects trying to identify new ways to target cancer. Together their goal is to find a cure for cancer. We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX Equipment. She accepts multiple insurance plans. S Kummar, A Chen, J Ji, Y Zhang, JM Reid, M Ames, L Jia, M Weil, K Do, D Wilsker, J Ji, J Zlott, T Freshwater, RJ Kinders, J Collins, AP Chen, Journal of Clinical Oncology 33 (30), 3409. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. The unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. (44 Ratings, S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, Clinical Cancer Research 18 (6), 1726-1734. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . She currently practices at Oregon Health And Sciencs University Primary Care Clinic and is affiliated with Stanford Health Care. The Division of Hematology and Medical Oncology is headed byShivaani Kummar, M.D., FACPand composed of many sections: Kathleen Beebe Sort by citations Sort by year Sort by title. Philanthropy will allow us to expand the number of ongoing projects, including those focusing on rare tumors, as well as take on more pre- and post-doctoral students to train the next generation of cancer researchers. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. Drukers approach to team science is incorporated throughout the institutes infrastructure. Administrative Coordinator, Karri Garaventa Across OHSU, doctors and researchers are reimagining early disease detection. Nature reviews Drug discovery 9 (11), 843-856. For help with all referral needs and questions, visit Referring Physicians. The institute is involved with more than 400 clinical trials, including 113 early-phase trials. OHSU is an equal opportunity affirmative action institution. Cited by. Combining PARP Inhibitor with Immunotherapy - Does the Promise of Preclinical Data Translate to Clinic? These new drugs go through very rigorous testing in the laboratory and only if they meet certain criteria as promising anticancer agents, we bring them forward into the first phase of human clinical trials. Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. Administrative Coordinator, Denise Hopkins Dr. Kummar loves to spend time with her family, read, and go for long walks. L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, S Kummar, A Chen, RE Parchment, RJ Kinders, J Ji, JE Tomaszewski, AF Farago, MS Taylor, RC Doebele, VW Zhu, S Kummar, AI Spira, S Kummar, M Gutierrez, ER Gardner, E Donovan, K Hwang, EJ Chung, Clinical Cancer Research 13 (18), 5411-5417. What are the latest results? mollie hemingway face shivaani kummar ohsu email. We have a number of clinical trials investigating promising new strategies to treat cancer. Malhotras background is in chemical biology and drug development with a strong expertise in medicinal chemistry, including small molecule synthesis. Dr. Shivaani Kummar has primarily specialised in Medical Oncology for over 31 years. Palliative Care Administrative Assistant. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC Its staff of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Response to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. OHSU is an equal opportunity affirmative action institution. Shivaani Kummar, M.D., FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. To find better ways to treat patients. February 17, 2023. middlesex county community college nursing program nj OHSU Knight Cancer Institute is a national leader in cancer research and training and well-known for its ability to turn cancer research discoveries into new cancer treatments. Accepting new patients ( ) (MCI) 'BAL0891' 1 27 . 5 , IND transfer 4 . 23() 'Oregon Health . Very few institutions do it well, but OHSU truly gets it, Kummar says. These topic labels come from the works of this person. Then we try to find what we call targets within or around cancer cells and develop drugs that can precisely hit those targets. Dr. Drukers vision for the field of translational oncology is similar to our vision of how to move discoveries from laboratories towardthe clinic. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Her research interests focus on developing novel therapies for cancer. We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. (OHSU/Joe Rojas-Burke). Dr. Hamburger Menu x Home (OHSU/Joe Rojas-Burke), Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Health and Healing Building 2 on OHSU's South Waterfront campus, Aug. 23, 2021. Select a country/territory to view shared publications and projects. In 2021, we held our 4th Stat4Onc Symposium virtually by Stanford University. 2001-2022 Oregon Health & Science University. (OHSU/Joe Rojas-Burke), The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. Clinical trials Drug development oncology. The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development. The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. Try restaurant style recipes at home. Trisha Silbernagel, RN, BSN, early-phase clinical trial unit manager, checks equipment on Aug. 23, 2021. OHSU is an equal opportunity affirmative action institution. Support the Abortion Care and Training Fund. Dr. Kummar specializes in the care and treatment of patients with cancer. Dr. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. We have a billion reasons why you should join us. Sort. If you proceed in scheduling an appointment and your healthinsurancebenefits do not participate with OHSU providers, your out of pocket liability may be higher. The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. Developing new treatments for cancer is a complex, multidisciplinary process that truly takes a village. Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD OHSU is an equal opportunity affirmative action institution. Vol.49 No.07. Leadership The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. By Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh Carlson | American Journal of Managed Care ABSTRACTThe tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. Shivaani Kummar, M.D., FACP Lisa M. Coussens, M.D. We are thrilled he is able to co-lead this new venture. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. They have a high school-aged daughter and middle school-aged son. billing andinsurancesection of our site, Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, American Board of Internal Medicine Board Certified in Internal Medicine, 1995-2005, Board Recertified in Internal Medicine, 2005-2015, Board Certified in Medical Oncology, 1998-2008, Board Recertified in Medical Oncology, 2008-2018; 2018-2028 Board Certified in Hematology, 2002-2012, Member, American Society of Clinical Oncology, Member, American Association for Cancer Research. 2001-2023 OHSU. Shivaani Kummar is a Hematology & Medical Oncology Head at Oregon Health & Science University based in Portland, Oregon. At the end of the day, we need to develop better treatment for cancer patients and the only way to build that is through collaboration within OHSU and with other academic centers, biotech and pharma companies., Team science can be a buzz word. Keep me signed in. Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer Research', 'Montefiore Medical Center' 4 1 .